Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.

ABSTRACT:

Background

Prevalence of chronic hepatitis C virus (HCV) infection is high among incarcerated persons in the United States. New, short-duration, high-efficacy therapies may expand treatment eligibility in this population.

Objective

To assess the cost-effectiveness of sofosbuvir for HCV treatment in incarcerated populations.

Design

Markov model.

Data sources

Published literature and expert opinion.

Target population

Treatment-naive men with chronic, genotype 1 HCV monoinfection.

Time horizon

Lifetime.

Perspective

Societal.

Intervention

No treatment, 2-drug therapy (pegylated interferon and ribavirin), or 3-drug therapy with either boceprevir or sofosbuvir. For inmates with short remaining sentences (<1.5 years), only no treatment or s

SUBMITTER: Liu S 

PROVIDER: S-EPMC4313741 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature